Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of “Buy” by Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have received an average recommendation of “Buy” from the nine research firms that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $39.86.

ORKA has been the subject of a number of analyst reports. Wolfe Research initiated coverage on shares of Oruka Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $20.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research report on Friday, February 7th. Finally, Wedbush reissued an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research report on Friday, March 7th.

Insider Buying and Selling

In other Oruka Therapeutics news, major shareholder Venrock Healthcare Capital Par acquired 8,971 shares of the company’s stock in a transaction dated Wednesday, February 12th. The stock was bought at an average price of $11.86 per share, with a total value of $106,396.06. Following the completion of the transaction, the insider now directly owns 4,044,684 shares of the company’s stock, valued at approximately $47,969,952.24. The trade was a 0.22 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders purchased 98,339 shares of company stock valued at $1,128,456. Insiders own 22.67% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

Large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. acquired a new stake in shares of Oruka Therapeutics in the fourth quarter worth $54,000. AlphaCentric Advisors LLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter worth $119,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Oruka Therapeutics in the fourth quarter worth $144,000. Squarepoint Ops LLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter worth $236,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Oruka Therapeutics in the fourth quarter worth $303,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Trading Up 1.1 %

ORKA stock opened at $11.06 on Wednesday. The stock has a market capitalization of $387.09 million, a P/E ratio of -1.77 and a beta of 0.67. Oruka Therapeutics has a 52 week low of $9.44 and a 52 week high of $31.13. The business’s 50-day moving average is $12.94.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Thursday, March 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.19. As a group, analysts predict that Oruka Therapeutics will post -3.41 earnings per share for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.